135 related articles for article (PubMed ID: 32184968)
1. Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors.
Manz TD; Sivakumaren SC; Yasgar A; Hall MD; Davis MI; Seo HS; Card JD; Ficarro SB; Shim H; Marto JA; Dhe-Paganon S; Sasaki AT; Boxer MB; Simeonov A; Cantley LC; Shen M; Zhang T; Ferguson FM; Gray NS
ACS Med Chem Lett; 2020 Mar; 11(3):346-352. PubMed ID: 32184968
[TBL] [Abstract][Full Text] [Related]
2. Targeting the PI5P4K Lipid Kinase Family in Cancer Using Covalent Inhibitors.
Sivakumaren SC; Shim H; Zhang T; Ferguson FM; Lundquist MR; Browne CM; Seo HS; Paddock MN; Manz TD; Jiang B; Hao MF; Krishnan P; Wang DG; Yang TJ; Kwiatkowski NP; Ficarro SB; Cunningham JM; Marto JA; Dhe-Paganon S; Cantley LC; Gray NS
Cell Chem Biol; 2020 May; 27(5):525-537.e6. PubMed ID: 32130941
[TBL] [Abstract][Full Text] [Related]
3. Discovery and Structure-Activity Relationship Study of (
Manz TD; Sivakumaren SC; Ferguson FM; Zhang T; Yasgar A; Seo HS; Ficarro SB; Card JD; Shim H; Miduturu CV; Simeonov A; Shen M; Marto JA; Dhe-Paganon S; Hall MD; Cantley LC; Gray NS
J Med Chem; 2020 May; 63(9):4880-4895. PubMed ID: 32298120
[TBL] [Abstract][Full Text] [Related]
4. The rational design of ARUK2007145, a dual inhibitor of the α and γ isoforms of the lipid kinase phosphatidylinositol 5-phosphate 4-kinase (PI5P4K).
Aldred GG; Rooney TPC; Willems HMG; Boffey HK; Green C; Winpenny D; Skidmore J; Clarke JH; Andrews SP
RSC Med Chem; 2023 Oct; 14(10):2035-2047. PubMed ID: 37859710
[TBL] [Abstract][Full Text] [Related]
5. Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.
Willems HMG; Edwards S; Boffey HK; Chawner SJ; Green C; Romero T; Winpenny D; Skidmore J; Clarke JH; Andrews SP
RSC Med Chem; 2023 May; 14(5):934-946. PubMed ID: 37252102
[TBL] [Abstract][Full Text] [Related]
6. A targeted library screen reveals a new inhibitor scaffold for protein kinase D.
Tandon M; Wang L; Xu Q; Xie X; Wipf P; Wang QJ
PLoS One; 2012; 7(9):e44653. PubMed ID: 23028574
[TBL] [Abstract][Full Text] [Related]
7. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A
Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749
[TBL] [Abstract][Full Text] [Related]
8. Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors.
Rewcastle GW; Kolekar S; Buchanan CM; Gamage SA; Giddens AC; Tsang KY; Kendall JD; Singh R; Lee WJ; Smith GC; Han W; Matthews DJ; Denny WA; Shepherd PR; Jamieson SMF
Oncotarget; 2017 Jul; 8(29):47725-47740. PubMed ID: 28537878
[TBL] [Abstract][Full Text] [Related]
9. Structure and Characterization of a Covalent Inhibitor of Src Kinase.
Gurbani D; Du G; Henning NJ; Rao S; Bera AK; Zhang T; Gray NS; Westover KD
Front Mol Biosci; 2020; 7():81. PubMed ID: 32509799
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 5-phosphate 4-kinase γ (PI5P4Kγ), a lipid signalling enigma.
Giudici ML; Clarke JH; Irvine RF
Adv Biol Regul; 2016 May; 61():47-50. PubMed ID: 26710750
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and structure-activity relationship studies of pyrido[2,3-d]pyrimidin-7-ones as potent Janus Kinase 3 (JAK3) covalent inhibitors.
Su W; Chen Z; Liu M; He R; Liu C; Li R; Gao M; Zheng M; Tu Z; Zhang Z; Xu T
Bioorg Med Chem Lett; 2022 May; 64():128680. PubMed ID: 35306167
[TBL] [Abstract][Full Text] [Related]
12. Relative Selectivity of Covalent Inhibitors Requires Assessment of Inactivation Kinetics and Cellular Occupancy: A Case Study of Ibrutinib and Acalabrutinib.
Hopper M; Gururaja T; Kinoshita T; Dean JP; Hill RJ; Mongan A
J Pharmacol Exp Ther; 2020 Mar; 372(3):331-338. PubMed ID: 31871305
[TBL] [Abstract][Full Text] [Related]
13. Expanding role of PI5P4Ks in cancer: A promising druggable target.
Arora GK; Palamiuc L; Emerling BM
FEBS Lett; 2022 Jan; 596(1):3-16. PubMed ID: 34822164
[TBL] [Abstract][Full Text] [Related]
14. Evolutionarily conserved structural changes in phosphatidylinositol 5-phosphate 4-kinase (PI5P4K) isoforms are responsible for differences in enzyme activity and localization.
Clarke JH; Irvine RF
Biochem J; 2013 Aug; 454(1):49-57. PubMed ID: 23758345
[TBL] [Abstract][Full Text] [Related]
15. Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors.
Qu L; Chen X; Wei H; Guo M; Dai S; Jiang L; Li J; Yue S; Chen Z; Chen Y
Commun Chem; 2022 Jan; 5(1):5. PubMed ID: 36697561
[TBL] [Abstract][Full Text] [Related]
16. Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors.
Zhou H; McGowan MA; Lipford K; Christopher M; Fradera X; Witter D; Lesburg CA; Li C; Methot JL; Lampe J; Achab A; Shaffer L; Goldenblatt P; Shah S; Bass A; Schroeder G; Chen D; Zeng H; Augustin MA; Katz JD
Bioorg Med Chem Lett; 2020 Jan; 30(1):126715. PubMed ID: 31757666
[TBL] [Abstract][Full Text] [Related]
17. Optimization of a novel piperazinone series as potent selective peripheral covalent BTK inhibitors.
Ma B; Metrick CM; Gu C; Hoemberger M; Bajrami B; Bame E; Huang J; Mingueneau M; Murugan P; Santoro JC; Tang H; Wang T; Hopkins BT
Bioorg Med Chem Lett; 2022 Mar; 60():128549. PubMed ID: 35041943
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
He L; Shao M; Wang T; Lan T; Zhang C; Chen L
Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a first-in-class Aurora A covalent inhibitor for the treatment of triple negative breast cancer.
Zhang B; Zhu C; Chan ASC; Lu G
Eur J Med Chem; 2023 Aug; 256():115457. PubMed ID: 37207533
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
